UBS Adjusts Price Target on Elevance Health to $460 From $400, Maintains Buy Rating
UBS has increased its price target for Elevance Health (ELV) to $460 from $400, while reconfirming a Buy rating on the stock. This adjustment reflects a positive outlook for the managed healthcare provider. The article also lists recent insider transactions and other analyst revisions for Elevance Health.
UnitedHealth Group (UNH) – Among the 10 High Quality Stocks to Buy According to Hedge Funds
UnitedHealth Group (UNH) is listed among the top 10 high-quality stocks favored by hedge funds. Analysts from UBS and BofA recently raised their price targets on UNH, citing strong Q1 results, improved Medicare Advantage rates, and confidence in margin recovery despite ongoing cost pressures from specialty drugs and behavioral health. The company, a major healthcare and well-being provider, encompasses Optum and UnitedHealthcare segments, demonstrating a bullish outlook from its leadership.
Glenview Capital sells 3.75M CVS shares, keeps it a top-3 holding
Glenview Capital has rebalanced its investment in CVS Health, selling 3.75 million shares after an 80% total return since May 2024. Despite this reduction for diversification, CVS remains one of Glenview's top three holdings, and the firm expresses strong confidence in its near, medium, and long-term outlook. The rebalancing followed healthy Q1 results and increased annual guidance for CVS.
Gordon Reid's Top Picks: Apple Inc, Celanese & Visa
Gordon Reid, President and CEO of Goodreid Investment Counsel, shares his top stock picks which include Apple Inc., Celanese, and Visa. The article highlights his current recommendations for investors looking to the market. This content is part of the "Market Call" series, featuring expert insights on stock selections.
UnitedHealth Group Incorporated stock (US91324P1021): Shares slide after Medicare and earnings press
UnitedHealth Group's stock remains volatile due to investor reassessment of growth in managed care, Medicare-related pressure, and earnings outlook. The company operates through UnitedHealthcare, its insurance platform, and Optum, which provides pharmacy and care services, giving it exposure to various aspects of the healthcare industry. While expected to grow, the stock faces risks from medical-cost trends, regulatory scrutiny, and policy changes affecting Medicare Advantage and drug pricing.
Two USPSTF leaders fired, sparking concern about panel's credibility
Two U.S. Preventive Services Task Force (USPSTF) chairs were terminated by HHS Secretary Robert F. Kennedy Jr., raising concerns among public health experts about the panel's independence and its future. This move comes as the panel has not met for over a year, has many vacant seats, and the Trump Administration has shown interest in restructuring it. Industry professionals and organizations like AcademyHealth and the American Medical Association are advocating for a transparent and unbiased process for appointing new members to protect access to free preventive services mandated by the Affordable Care Act.
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV)
This article highlights bullish analyst ratings for two healthcare companies: Protara Therapeutics (TARA) and Elevance Health (ELV). H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating for Protara Therapeutics with a $27.00 price target, while Wells Fargo analyst Stephen Baxter maintained a Buy rating for Elevance Health with a $391.00 price target. The article details analyst consensus ratings and price targets, indicating significant upside potential for Protara and a slight upside for Elevance Health.
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders
Humana (HUM) recently expanded its Medicare Advantage coverage for CVRx Inc.'s Barostim therapy, effective May 1, 2026, benefiting approximately 5.2 million Medicare Advantage members with eligible heart failure. This move aligns with Humana's strategy to enhance clinical quality and control costs, though regulatory shifts and existing financial uncertainties for Humana still warrant careful investor consideration. The decision is seen as supportive of advanced heart failure care, impacting Humana's investment narrative within the broader context of its financial forecasts and market valuation.
Elevance Health (NYSE: ELV) CAO exercises options, sells 1,531 shares
Elevance Health's Chief Accounting Officer, Ronald W. Penczek, exercised employee stock options for 1,531 shares and subsequently sold all of them in an open-market transaction at $403.13 per share. After these transactions, Penczek directly holds 4,109 shares of common stock, which includes some shares acquired through a dividend reinvestment plan. The total value of the shares sold was approximately $617,192.
Private payer rates outpaced Medicare's by 47%: KFF
A new KFF analysis reveals that private payer rates for hospital care increased 47% faster than Medicare rates between April 2019 and April 2026, with private payer prices rising 30% compared to Medicare's 21%. This widening gap is attributed to factors like hospital consolidation and shifts in bargaining power. Lawmakers and policymakers are scrutinizing hospitals over rising costs, proposing measures like stronger antitrust enforcement and price transparency, while hospitals argue that increasing costs of care and insufficient Medicare reimbursement justify their pricing.
Elevance Health Inc. stock outperforms competitors despite losses on the day
Despite a daily loss of 1.51%, Elevance Health Inc. (ELV) stock closed at $396.21 on Wednesday, outperforming competitors and the broader market. This occurred on a strong trading day where the S&P 500 Index rose 1.08% and the Dow Jones Industrial Average gained 1.31%. The stock's dip ended a two-day winning streak.
Elevance Health Is Maintained at Outperform by Mizuho
Mizuho has maintained an "Outperform" rating on Elevance Health (ELV), indicating a positive outlook for the company's stock. The article also briefly mentions Unity Software's (U.US) fourth-quarter financial results, noting a revenue increase of 35% year-over-year to $609 million, which beat analyst estimates, despite a quarterly loss of 66 cents per share.
Low digital health literacy hamstrings seniors' health IT use
A report from CVS Health reveals that low digital health literacy significantly impacts seniors, preventing 58% of Medicare enrollees aged 65 and older from fully managing their health. Despite this, 86% of seniors are open to using health IT, highlighting a crucial opportunity for healthcare organizations to implement human-led educational programs. The findings challenge the assumption that older adults are resistant to technology, emphasizing the need for accessible resources to bridge the digital health literacy gap.
UnitedHealth Group Incorporated stock (US91324P1021): Q1 numbers, Medicare pressure and what’s nex
UnitedHealth Group (UNH) remains a focused healthcare stock due to its latest quarterly report and the ongoing impact of the Change Healthcare cyberattack. The company reported revenue growth but also higher medical cost trends in Q1 2026. This article explores UnitedHealth’s business model, key revenue drivers, industry trends, and competitive position, highlighting its importance for US investors despite regulatory and operational challenges.
Is Alignment Healthcare’s (ALHC) Index Debut and Leadership Shuffle Reframing Its Long-Term Strategic Ambitions?
Alignment Healthcare (ALHC) recently underwent a leadership reshuffle, with founder John Kao becoming Chairman and new senior hires taking COO and MSO President roles. Concurrently, the company was added to the S&P SmallCap 600 and S&P Composite 1500, potentially increasing its investor base and visibility. These changes occur as Alignment Healthcare aims for significant revenue and earnings growth by 2029 through its tech-enabled Medicare Advantage model, though management of medical costs and regulatory risks remain critical for its profitability.
This CH Robinson Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
A Benzinga article details five significant analyst upgrades for Wednesday. Key upgrades include SM Energy by Raymond James, Rubrik Inc by Oppenheimer, C.H. Robinson Worldwide Inc by Jefferies, and both Elevance Health Inc and Centene Corp by Deutsche Bank, with each receiving a raised price target. The article highlights how these Wall Street analysts are changing their outlook on these top names, encouraging investors to review the complete list of analyst rating changes on their dedicated page.
Berkshire Exit Puts Spotlight On UnitedHealth Earnings Strength And Regulatory Risks
Berkshire Hathaway has fully exited its stake in UnitedHealth Group (NYSE:UNH) after less than a year, prompting investors to re-evaluate the company's risk profile, particularly concerning regulatory scrutiny and cost pressures. While some see this as a red flag, other large institutions and analysts remain positive, citing UnitedHealth's scale and efficiency efforts. This exit amplifies attention on potential downside risks despite recent strong earnings and raised guidance.
ELV (NYSE: ELV) Form 144 filed for 1,531 shares on 05/19/2026
Elevance Health, Inc. (NYSE: ELV) filed a Form 144 on May 19, 2026, announcing the proposed sale of 1,531 common shares. This filing details two stock option exercises, one for 654 shares and another for 877 shares, both dated May 19, 2026, with Morgan Stanley Smith Barney LLC identified as the broker/dealer. The transactions are related to an Issuer stock option exercise on the NYSE.
Elevance Health Inc. stock outperforms competitors on strong trading day
Shares of Elevance Health Inc. (ELV) rose 2.08% to $402.27 on Tuesday, continuing its two-day gaining streak. This performance stood out on a generally poor trading day where the S&P 500 Index and Dow Jones Industrial Average both saw declines.
UnitedHealth Under the Microscope After Berkshire Pulls the Plug
Berkshire Hathaway has sold its entire stake in UnitedHealth Group, causing UNH shares to drop 2%. This exit, part of a broader portfolio re-shuffle under Berkshire's new CEO Greg Abel, has raised questions, although some see it as profit-taking rather than a fundamental issue with the company. Key concerns like elevated medical costs and regulatory scrutiny that Berkshire initially overlooked still persist, even as UnitedHealth's stock performance has improved year-to-date.
How providers are responding to Elevance’s out-of-network policy
This article discusses how healthcare providers are reacting to Elevance Health's out-of-network referral penalties. The author, Caroline Hudson, published this piece on May 19, 2026. The content briefly explains the situation and likely delves into the nuances of provider responses to such policies.
GoHealth (NASDAQ: GOCO) posts steep Q1 2026 revenue drop and flags going‑concern risk
GoHealth (NASDAQ: GOCO) reported a significant revenue decline and widened net loss in Q1 2026, leading its management to express substantial doubt about the company's ability to continue as a going concern. The company's net revenues plummeted to $11.9 million from $221.0 million year-over-year, largely due to a strategic pullback in Medicare Advantage activities and high operating costs and debt interest. GoHealth is actively discussing strategic alternatives, including potential restructuring or a change of control, with its lenders to address liquidity issues and upcoming financial covenants.
How providers are responding to Elevance’s out-of-network policy
Elevance Health has implemented a new policy imposing administrative penalties on hospitals that refer certain patients to out-of-network clinicians. The article, authored by Caroline Hudson, explores how healthcare providers are reacting to this change. It also features related stories on Medicaid Fraud Control Units, hospital operating room strategies, and AI tools for sepsis.
Most older Americans say low digital literacy harms health
A CVS Health study revealed that 58% of Medicare-eligible older Americans believe low digital literacy negatively impacts their health management, with 85% struggling to navigate digital health platforms. However, 86% are open to using these tools, and 71% desire more engagement. CVS Health is addressing this gap through a $20 billion technology investment focused on intuitive tools, personalized care paths, and community-based education to improve accessibility and support for this growing, complex population.
Helping seniors navigate digital-first health care
As digital-first health care becomes more common, many older adults struggle with digital health literacy, impacting their ability to manage health tasks. Research shows over 7 in 10 Medicare members feel confusion navigating online health information, underscoring the need for tailored digital experiences and support. CVS Health is addressing this by designing simpler digital tools, offering conversational AI navigation, and providing in-person support and classes to improve accessibility and trust for seniors.
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care
Elevance Health is committing $23 million through its Foundation to address critical gaps in mental health care across the U.S., focusing on improving access, affordability, and quality of treatment. The initiative combines clinical programs, digital care navigation, and community partnerships to simplify the mental health journey and prevent crises. This effort includes funding organizations providing early intervention, especially for youth, and reducing the stigma associated with mental health conditions.
Bessemer Group Inc. Sells 4,178 Shares of Elevance Health, Inc. $ELV
Bessemer Group Inc. reduced its stake in Elevance Health (NYSE:ELV) by 2.8% in the fourth quarter of 2025, selling 4,178 shares but still holding 143,194 shares valued at $50.2 million. Institutional ownership of Elevance Health remains high at 89.24%, with several other major funds increasing their positions significantly. Elevance Health surpassed Q4 earnings expectations with $12.58 EPS and $49.49 billion in revenue, leading analysts to maintain a "Moderate Buy" rating with an average target price of $384.58.
Gail Boudreaux
Gail Boudreaux is the president and CEO of Elevance Health, one of the largest health insurers in the United States. She was a star basketball player at Dartmouth College, where she set multiple Ivy League records and attributed her athletic background to her management style in business. Boudreaux joined Anthem, Inc. (now Elevance Health) in 2017 and has overseen its expansion and rebranding, emphasizing teamwork and clearly defined roles in her leadership.
Elevance Health (ELV) director Ramiro Peru receives 563 deferred stock units as board pay
Elevance Health director Ramiro G. Peru was granted 563 deferred stock units as part of his board compensation, increasing his direct holdings to 9,908 shares. These units, awarded at no cash cost, will convert to common stock five years from the grant date or upon his departure from the board, unless a later payout date is elected. The transaction is a routine equity grant, not an open-market purchase, and is considered a neutral event for the stock.
Board member gets 563 deferred stock units at Elevance Health (NYSE: ELV)
Elevance Health director Antonio F. Neri was granted 563 deferred stock units as part of the company's Board of Directors Compensation Program, increasing his direct holdings to 5,488 shares. These units, awarded at no cash cost, will convert to common stock after five years or upon his departure from the board, unless a later payout is elected. This is a routine, compensation-related equity award rather than an open-market purchase.
Elevance Health (ELV) director Amy Schulman receives 563 deferred stock units
Elevance Health (ELV) director Amy W. Schulman received 563 deferred stock units as compensation under the company's Board of Directors Compensation Program. This grant increased her direct equity-related position to 781 shares-equivalent. These units are payable in common stock upon the earlier of five years from the grant date or her departure from the board, unless a later date is elected.
Director at Elevance Health (ELV) receives 563 deferred stock units as board compensation
Elevance Health director Deanna D. Strable-Soethout was granted 563 deferred stock units as part of her board compensation, bringing her total holdings to 2,209 units. These units were awarded at no cash cost and will be settled in common stock either five years from the grant date or upon her departure from the board, unless a later payout is chosen. This transaction, detailed in a Form 4 filing, is an equity award for compensation, not a market purchase or sale.
Director at Elevance Health (NYSE: ELV) receives 563 deferred units
Steven H. Collis, a director at Elevance Health (NYSE: ELV), has been granted 563 deferred stock units as part of the company's Board of Directors Compensation Program. These units, granted at no cash price, increase his direct holdings to 4,202 units. The deferred stock units will convert to common stock either five years from the grant date or when Collis leaves the board, unless a later date is elected.
Elevance Health Inc. stock outperforms competitors despite losses on the day
Elevance Health Inc. (ELV) saw its stock decrease by 1.02% to $392.68, marking its second consecutive day of losses. Despite this, the company's stock outperformed the broader market, as the S&P 500 Index fell by 1.24% and the Dow Jones Industrial Average fell by 1.07% on the same day.
Greene County hospital serves Anthem with second breach notice over claim payments
Greene County General Hospital has issued a second notice of breach of contract to Anthem Blue Cross and Blue Shield of Indiana, alleging consistent underpayments and delayed responses to claims. The hospital claims Anthem owes it millions of dollars, jeopardizing its financial stability and ability to serve the community. Despite an ongoing legal battle and previous breach notices, the issues persist.
Elevance Health Shareholders Back Directors, Pay and Auditor
Elevance Health shareholders re-elected three directors, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor at their annual meeting. They also rejected a proposal for an independent study on political contributions to 527 groups. TipRanks' AI Analyst, Spark, rated ELV as "Outperform," highlighting strong financial performance, reasonable valuation, and positive technical momentum.
Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
Alignment Healthcare has been recognized by the Pharmacy Quality Alliance (PQA) for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan, one of only four such plans nationally to receive the 2026 Excellence in Quality Award. This marks the seventh time Alignment has received this award, highlighting its commitment to medication safety, adherence, and personalized care for seniors. The recognition is based on achieving a 5-star rating across five specific PQA medication measures, reinforcing the company's efforts to improve health outcomes for its members.
Humana stock (US4456581077): Partners with VFW for veteran support on May 19
Humana Inc., in partnership with CenterWell, USAA, VFW, and Volunteers of America, will host a National Day of Service on May 19 to aid homeless veterans across three cities. The initiative focuses on assembling 4,000 care kits and supporting at-risk veterans and seniors. This effort highlights Humana's dedication to social impact, complementing its Medicare Advantage operations and reinforcing its role in the US healthcare sector.
bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF
This page provides recent news headlines related to bioAffinity Technologies, Inc. (Nasdaq: BIAF), mostly focusing on stock movements, top gainers, and losers in various trading sessions. It aggregates news from sources like Chartmill and Benzinga, with some articles highlighting healthcare stocks and specific company performance. The latest stock price for BIAF is also provided, showing a slight increase.
Why UnitedHealthcare and other insurers are padding reserves
Major health insurance companies, including UnitedHealthcare, Elevance Health, and Alignment, are actively increasing their financial reserves. This move involves bolstering their financial cushions to manage potential future claims or financial risks more effectively. The article, by Noah Tong, specifically highlights this trend among prominent insurers.
Elevance Health stock (US2855211023): Leading US health insurer navigates sector challenges
Elevance Health, a major US health insurer with over 47 million members, continues to demonstrate strong performance with $43.2 billion in Q1 2026 revenue, up 4% year-over-year. The company strategically focuses on Medicare Advantage and cost management, leveraging its diversified portfolio and integrated care model through subsidiaries like Carelon. Elevance Health's position in the dynamic US healthcare market, facing regulatory and cost pressures, makes it a compelling option for investors seeking exposure to the $4.5 trillion American healthcare economy.
Why UnitedHealthcare and other insurers are padding reserves
Major health insurance companies like UnitedHealthcare and Elevance Health are increasing their reserves. The article, authored by Noah Tong, details why these insurers are choosing to bolster their financial cushions. This move is a significant development in the insurance industry, indicating a proactive approach to financial stability.
Elevance Health Shareholders Back Directors, Pay and Auditor
Elevance Health shareholders re-elected three directors, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor at their annual meeting on May 13, 2026. They also rejected a proposal to limit partisan political contributions. TipRanks' AI Analyst, Spark, rates ELV as "Outperform" citing solid financial performance and reasonable valuation, despite some industry pressures.
Elevance Health shareholders elect directors and approve executive pay at annual meeting
Elevance Health shareholders held their annual meeting, electing three directors—Gail K. Boudreaux, Robert L. Dixon, Jr., and Deanna D. Strable—to three-year terms. They also approved the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as their independent registered public accounting firm. A shareholder proposal regarding corporate contributions to partisan 527 tax-exempt political groups was not approved.
Elevance Health (ELV) 2026 annual meeting: directors elected, pay and auditor backed
Elevance Health (ELV) held its 2026 annual shareholder meeting where three directors were elected for three-year terms. Shareholders also approved executive compensation on an advisory basis and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026. A shareholder proposal regarding a study on prohibiting corporate contributions to partisan 527 tax-exempt political groups did not pass.
Elevance Health stock (US2855211023): Health insurance giant reports strong Q1 amid sector shifts
Elevance Health reported strong Q1 2026 results with revenue of $46.9 billion and adjusted EPS of $10.68, surpassing estimates and leading to a raised full-year EPS guidance. The health insurance giant, serving over 47 million members, saw its shares rise 2.1% post-earnings, reflecting market approval of its diversified business model, stable government revenue, and Carelon unit growth. US investors view ELV as a key proxy for domestic healthcare trends, balancing growth and defensive qualities in their portfolios.
‘Glimmers of hope’ seen for insurers as medical costs abate
The health insurance sector is showing signs of recovery after several challenging years, as major insurers like UnitedHealth, CVS, and Cigna report an easing of medical costs. This development suggests a potential positive shift for the industry. The article highlights these "glimmers of hope" as observed in recent earnings reports from key players.
What Does Elevance Health's Q1 2026 Performance Signal for Investors
Elevance Health (ELV) reported strong Q1 2026 results, surpassing earnings and revenue estimates and leading to an upward revision in its full-year adjusted EPS guidance. Despite regulatory pressures and rising medical costs, the company's strategic focus on its Carelon services and operational efficiency positions it for continued growth. ELV also reaffirmed its commitment to shareholder returns through a $1.72 quarterly dividend and substantial share buybacks, suggesting confidence in its financial stability and future prospects, making it a potentially attractive investment.
Alignment Healthcare Names John Kao Chairman, Shane Hochradel COO
Alignment Healthcare has appointed John Kao as its new Chairman and Shane Hochradel as Chief Operating Officer. The article also briefly mentions Unity Software's Q4 financial results, with revenue increasing 35% year-over-year to $609 million, exceeding analyst estimates, despite reporting a quarterly loss of 66 cents per share.
Elevance Health Inc (BSP:E1LV34) Stock Price & 30 Year Financial Data
This article from GuruFocus provides detailed 30-year financial data for Elevance Health Inc (BSP:E1LV34), including growth rates for revenue, EPS, EBITDA, free cash flow, and dividends. It also lists key financial metrics such as market cap, enterprise value, P/E ratio, and P/B ratio, along with a GF Score, offering a comprehensive overview for investors. The platform emphasizes data transparency and offers various tools for financial analysis.
